United States

People: Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

16 Mar 2018
Change (% chg)

$0.05 (+0.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Parsons, James 

Mr. James T. Parsons, CPA, is Chief Financial Officer of the Company. Mr. Parsons is the Chief Financial Officer of Trillium since August 25, 2011 and was also the Director, Finance of Trillium Privateco. He was previously the Vice President, Finance of DiaMedica Inc. from October 2010 to May 2014, and Chief Financial Officer of Amorfix Life Sciences Ltd. from 2006 to 2010. Mr. Parsons sits on the board of Sernova Corp and DiaMedica Inc.

Basic Compensation

Total Annual Compensation, USD 681,192
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD 105,875
All Other, USD --
Fiscal Year Total, USD 787,067

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --